 Home > Active Ingredient News > Antitumor Therapy > AL101 treats three-negative breast cancer activated by the Notch signaling path

AL101 treats three-negative breast cancer activated by the Notch signaling path

 Last Update: 2021-02-03
 Source: Internet
 Author: User

Tags

nanotechnology cancer treatment

what gene expression

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Oncology company Ayala Pharmaceuticals announced today that phase II TENACITY clinical trials for patients with the selective small molecule AL101 to treat relapse or metastatic (R/M) triple negative breast cancer (TNBC) activated by the Notch signal path, have been officially launched.
Phase II study aims to assess the efficacy and safety of AL101 as a monotherapy for Notch-activated R/M TNBC patients.
this is an open, multi-center, one-arm study that is expected to initially recruit 26 Notch-activated R/M TNBC patients whose disease has relapsed or progressed after previous treatment.
will use second-generation sequencing (NGS) to determine The activation status of Notch.
Ayala expects to report preliminary data by the end of 2021.
AL101 is a small molecule γ secretion enzyme inhibitor (GSI) in the study designed to selectively inhibit Notch 1, 2, 3 and 4.
AL101 is designed to inhibit the expression of notch γ target gene by blocking the secretion enzymes needed to activate Notch.
previously, AL101 had been awarded "Fast Track Qualification" and "Orphan Drug Title" by the FDA to treat adenoblast-like cystic cancer (ACC).

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.